Sofinnova Venture Partners IX, L.P. 3
3 · Entasis Therapeutics Holdings Inc. · Filed Sep 25, 2018
Insider Transaction Report
Form 3
Sofinnova Venture Partners IX, L.P.
10% Owner
Holdings
Series B-1 Tranche B Convertible
→ Common Stock (9,502,249 underlying)Series B-1 Tranche A Convertible
→ Common Stock (7,446,904 underlying)
Footnotes (2)
- [F1]Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock is convertible at any time, at the option of the holder, into Common Stock, on a 20.728-for-one basis, has no expiration date and will convert into shares of Common Stock upon the closing of the Issuer's initial public offering.
- [F2]The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein.